Revisión de las terapias biológicas en la enfermedad inmunomediada del oído interno

Lobo, David; García-Berrocal, José Ramón; Trinidad, Almudena; Verdaguer, José María; Ramírez‐Camacho, Rafael

doi:10.1016/j.otorri.2012.04.008

Cited by 11 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that TNFα has differing ototoxic effects based on a given tumour’s secretome or other properties of the tumour. TNFα inhibition via monoclonal antibodies has been clinically successful in alleviating immune-mediated and idiopathic SNHL 34 , and our study suggests that it could also be beneficial for VS-mediated SNHL.…”

Section: Discussionmentioning

confidence: 57%

Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage

Dilwali

Landegger

Soares

et al. 2015

Sci Rep

109

120

View full text Add to dashboard Cite

Vestibular schwannomas (VSs) are the most common tumours of the cerebellopontine angle. Ninety-five percent of people with VS present with sensorineural hearing loss (SNHL); the mechanism of this SNHL is currently unknown. To establish the first model to study the role of VS-secreted factors in causing SNHL, murine cochlear explant cultures were treated with human tumour secretions from thirteen different unilateral, sporadic VSs of subjects demonstrating varied degrees of ipsilateral SNHL. The extent of cochlear explant damage due to secretion application roughly correlated with the subjects’ degree of SNHL. Secretions from tumours associated with most substantial SNHL resulted in most significant hair cell loss and neuronal fibre disorganization. Secretions from VSs associated with good hearing or from healthy human nerves led to either no effect or solely fibre disorganization. Our results are the first to demonstrate that secreted factors from VSs can lead to cochlear damage. Further, we identified tumour necrosis factor alpha (TNFα) as an ototoxic molecule and fibroblast growth factor 2 (FGF2) as an otoprotective molecule in VS secretions. Antibody-mediated TNFα neutralization in VS secretions partially prevented hair cell loss due to the secretions. Taken together, we have identified a new mechanism responsible for SNHL due to VSs.

show abstract

Section: Discussionmentioning

confidence: 57%

Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage

Dilwali

Landegger

Soares

et al. 2015

Sci Rep

109

120

View full text Add to dashboard Cite

show abstract

Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss

Mata‐Castro

López

Varillas‐Delgado

et al. 2019

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Audiovestibular outcomes in adult patients with cogan syndrome: a systematic review

Marrero-Gonzalez,

Ward,

Nguyen

et al. 2024

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose To determine factors associated with steroid responsiveness and efficacy of biologic disease-modifying anti-rheumatic (DMARD) use in patients with Cogan Syndrome (CS). Methods A systematic search of Cochrane Library, PubMed, CINAHL, and Scopus was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Any study describing audiometric or vestibular data and pharmacologic treatment in patients with CS was included. Due to limited literature, only case reports/case series were included. Results Seventy case reports or case series studies comprising 79 individual cases of CS were included. A difference in vestibular symptoms with a higher prevalence in the steroid-resistant group than the steroid-responsive group was found (79.5% vs 57.9%, p = 0.04). Eighteen (60.0%) patients treated only with oral steroids had no audiological improvement, while twelve (n = 12; 85.7%) patients treated with biologic DMARD showed audiological improvement. The steroid-responsive group had an overall better response to DMARDs than the steroid-resistant group (62.1% vs 45.0%; 100.0% vs 77.8%). Conclusions Our study synthesized the available literature to better characterize steroid resistance in patients with Cogan syndrome and treatment outcomes. Vestibular symptoms were noted to be more prevalent in patients who were eventually labeled as steroid resistant. There were higher rates of audiological improvement in patients given biologic DMARDs rather than conventional DMARDs or steroids only. Further studies are needed to characterize each individual vestibular symptom and investigate the utility and timing of biologic DMARDs in managing patients with Cogan syndrome.

show abstract

Revisión de las terapias biológicas en la enfermedad inmunomediada del oído interno

Cited by 11 publications

References 31 publications

Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage

Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage

Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss

Audiovestibular outcomes in adult patients with cogan syndrome: a systematic review

Contact Info

Product

Resources

About